Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 121 of the 122 references it cites were found in a registry or an index; none of the 197 sources its claims cite is checked for support yet.

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines

Open access
Madsbad, Sten, Holst, Jens J · 2025 · Expert Opinion on Investigational Drugs

Abstract

INTRODUCTION: GLP-1-based therapies have changed the treatment of overweight/obesity. Liraglutide 3.0 mg daily, the first GLP-1 RA approved for treatment of overweight, induced a weight loss of 6-8%, Semaglutide 2.4 mg once weekly improved weight loss to about 12-15%, while the dual GIP/GLP-1 receptor agonist tirzepatide once weekly has induced a weight loss of about 20% in obese people without diabetes. AREAS COVERED: This review describes results obtained with GLP-1 mono-agonists, GLP-1/GIP dual agonists, GLP-1/glucagon co-agonists, and the triple agonist retatrutide (GIP/GLP-1/glucagon), which have shown beneficial effect both on body weight and steatotic liver disease. A combination of semaglutide (a GLP-1 agonist) and cagrilintide (a long-acting amylin analogue) for weekly administration is currently in phase III development, and so is oral semaglutide and several non-peptide small molecule GLP-1 agonists for oral administration. The adverse events with the GLP-1-based therapies are primarily gastrointestinal and include nausea, vomiting, obstipation, or diarrhea, which often can be mitigated by slow up titration. EXPERT OPINION: The GLP-1-based therapies will change the treatment of obesity and its comorbidities including steatotic liver disease in the future. Outstanding question is maintenance of the weight loss, possibly pharmacological treatment needs to be life-long.

Overview

CoChat Summary

TL;DR

This narrative review summarizes phase 2/3 GLP-1-based obesity therapies, from liraglutide and semaglutide to dual/triple agonists such as tirzepatide, CagriSema, and retatrutide. It concludes these agents will change obesity and comorbidity treatment, but long-term maintenance, safety, cost, and lean-mass loss remain unresolved.

Key findings

  • Established GLP-1-based therapies produce escalating weight loss: liraglutide 3.0 mg induced 6–8%, semaglutide 2.4 mg about 12–15% (STEP 1: −14.9% vs −2.4% placebo at 68 weeks), and tirzepatide about 20% (SURMOUNT-1: −20.9% with 15 mg vs −3.1% placebo at 72 weeks).
  • In REDEFINE 1, CagriSema 2.4 mg produced −22.7% weight loss at 68 weeks vs −16.1% for semaglutide 2.4 mg, −11.8% for cagrilintide 2.4 mg, and −2.3% for placebo.
  • Retatrutide, a GIP/GLP-1/glucagon triple agonist, led to up to −24.2% weight loss at 48 weeks in a phase 2 trial (12 mg vs −2.1% placebo) and reduced liver fat by up to −86.0% at 48 weeks in a substudy.
  • Oral agents showed meaningful effects: oral semaglutide 50 mg gave −15.1% vs −2.4% placebo at 68 weeks; orforglipron gave −9.4% to −14.7% vs −2.3% placebo at 36 weeks; danuglipron phase 2b reached up to −13% vs −1.4% placebo at 32 weeks but with >50% discontinuation across doses.

Methods

  • Narrative review of GLP-1-based anti-obesity drugs, with a systematic literature search of published articles, reference lists, EASD/ADA abstract programs from the last 5 years, and pharmaceutical company press releases; focus on randomized controlled trials and English-language publications.
  • Data are drawn from phase 2/3 trials and press releases for liraglutide, semaglutide, tirzepatide, amylin analogues, dual GLP-1/GIP, GLP-1/glucagon, GLP-1/FGF-21, and triple agonists.
  • Main analysis is a narrative synthesis of body weight, glycemic, liver, cardiovascular, and adverse-event outcomes rather than a formal meta-analysis.

Limitations

  • The paper states limitations of GLP-1-based therapy: high cost, loss of lean body mass, gastrointestinal adverse events, and weight regain after stopping; long-term safety data are missing, with the longest placebo-controlled trial about 4 years.
  • The paper notes that data for newer GLP-1/glucagon agonists and GIP/GLP-1/glucagon triple agonists come primarily from short-term phase 2 studies with few participants, and individual weight-loss response cannot currently be predicted.
  • Evident from the text: several pipeline results rely on press releases or abstract presentations, and the review does not describe a formal risk-of-bias assessment or quantitative meta-analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/13543784.2025.2472408

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 9 Not valid · 179 Not checked · 40 Own results and interpretations

106 more claims

Create a free account to see all 228 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 55
  • The quote only partly states this claim. 3
  • It may state two separate claims as one. 75

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 122 references

Research works printed but not linked: 13

  1. Press release novo nordisk A/S 17. 2025 Jan.
  2. Semaglutide 2.4 mg demonstrated superior improvement in liver fibrosis and MASH resolution in the ESSENCE trial. Press release novo nordisk A/S 1. 2024 Nov.
  3. P press release 1. 2023 Dec. Available from: Www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r
  4. Press release Roche 17. 2024 Jul.
  5. Press release Novo Nordisk A/S 20. 2024 Dec.
  6. E Lilly Press release 4. 2024 Dec.
  7. Viking therapeutics press release. 2023 Oct 17.
  8. Viking-Therapeutics press release. 2024 Feb 27.
  9. Viking Therapeutics press release 4. 2024 Nov.
  10. Carmot therapeutic press release 15. 2024 May.
  11. Amgen press release 26. 2024 Nov.
  12. Altimmune press release. 2023 Jun.
  13. Altimmune press release. 2023 Sep.

Cited by

See all 43

Metadata

Authors
Madsbad, S., & Holst, J. J.
Affiliations
University of Copenhagen (DK)
Corresponding author
Madsbad, Sten
Venue
Expert Opinion on Investigational Drugs
Published
2025-03
Volume
34
Issue
3
Pages
197-215
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W4408078695
Cited by
43
References
122
Citations by year
2026: 27 · 2025: 16
FWCI
5.77
Type
journal article
Language
en
Open access
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
GLP-1 receptor agonists, obesity treatment, semaglutide, tirzepatide, liraglutide, cagrilintide, retatrutide, GIP/GLP-1 dual agonist, nonalcoholic steatohepatitis, weight loss maintenance, gastrointestinal adverse effects
MeSH terms
Liraglutide, Drug Development, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Glucagon-Like Peptides, Humans, Obesity, Weight Loss, Anti-Obesity Agents, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. https://app.cochat.ai/papers/10.1080/13543784.2025.2472408
The paper
Madsbad, S., & Holst, J. J. (2025). The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2025.2472408

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.